Full Text Journal Articles by
Author Richard H Aster

Advertisement

Find full text journal articles






How platelet transfusions were invented.

Richard H Aster,

Transfusion (Transfusion)
[2021, 61(12):3483-3486]

Cited: 0 times

View full text PDF listing >>



A prospective, blinded study of a PF4-dependent assay for HIT diagnosis.

Bethany Samuelson Bannow, Deepti M Warad, Curtis G Jones, Shannon M Pechauer, Brian R Curtis, Daniel W Bougie, Ruchika Sharma, Diane E Grill, Mary W Redman, Parisa R Khalighi, Rachel R Leger, Rajiv K Pruthi, Dong Chen, Daniel E Sabath, Richard H Aster, David A Garcia, Anand Padmanabhan,

Heparin-induced thrombocytopenia (HIT) is a life-threatening, prothrombotic, antibody-mediated disorder. To maximize the likelihood of recovery, early and accurate diagnosis is critical. Widely available HIT assays, such as the platelet factor 4 (PF4) heparin enzyme-linked immunosorbent assay (ELISA) lack specificity, and the gold-standard carbon 14-labeled serotonin release assay (SRA) is of ... Read more >>

Blood (Blood)
[2021, 137(8):1082-1089]

Cited: 5 times

View full text PDF listing >>



Advertisement

Characterization of glycoprotein IIb/IIIa-specific alloantibodies induced by cross-strain platelet immunization in mice.

Daniel W Bougie, Jessica Sutton, Richard H Aster,

<h4>Background</h4>We previously described a mouse model in which platelet immunization between selected strains leads to production of alloantibodies and severe autoimmune thrombocytopenia and mimics the human condition posttransfusion purpura (PTP). This report describes studies defining epitopes recognized by these alloantibodies.<h4>Study design</h4>Hybridomas were produced from spleen cells of immunized mice. Glycoprotein ... Read more >>

Transfusion (Transfusion)
[2021, 61(4):1278-1285]

Cited: 0 times

View full text PDF listing >>



Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report.

Joel Moore, Maria R Baer, Brian E Grover, Richard H Aster, Leah S Millstein,

Moxifloxacin is a rare but important cause of drug-induced immune thrombocytopenia (DIT). We describe a patient who presented with an acute onset of severe thrombocytopenia complicated by petechial rash, epistaxis, and melena. Recent new drug exposures included moxifloxacin and two proton pump inhibitors. On presentation to the hospital, all recently initiated medications ... Read more >>

Cureus (Cureus)
[2020, 12(9):e10507]

Cited: 0 times

View full text PDF listing >>



Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies.

Nanyan Zhang, Sentot Santoso, Richard H Aster, Brian R Curtis, Peter J Newman,

Human platelet membrane glycoprotein polymorphisms can be immunogenic in man and are frequently the cause of clinically important immune reactions responsible for disorders such as neonatal alloimmune thrombocytopenia. Platelets from individuals carrying rare polymorphisms are often difficult to obtain, making diagnostic testing and transfusion of matched platelets challenging. In addition, ... Read more >>

Blood (Blood)
[2019, 134(22):e1-e8]

Cited: 5 times

View full text PDF listing >>



Recapitulation of posttransfusion purpura by cross-strain platelet immunization in mice.

Daniel W Bougie, Jessica Sutton, Richard H Aster,

Posttransfusion purpura (PTP) is an uncommon but life-threatening condition characterized by profound thrombocytopenia occurring ∼1 week after a blood transfusion. The hallmark of PTP is a potent immunoglobulin G antibody specific for a transfused platelet-specific alloantigen, usually located on glycoprotein IIb/IIIa (GPIIb/IIIa; αIIb/β3 integrin). It is widely thought that this ... Read more >>

Blood Adv (Blood advances)
[2020, 4(2):287-295]

Cited: 2 times

View full text PDF listing >>



Post-Transfusion Purpura: Current Perspectives.

Jaleah Hawkins, Richard H Aster, Brian R Curtis,

Post transfusion purpura (PTP) is an uncommonly reported post transfusion adverse event that can present with severe thrombocytopenia; sometimes resulting in significant bleeding and hemorrhage. Its diagnosis can be elusive given its substantial symptomatic overlap with other thrombocytopenic syndromes. Underdiagnosis and underreporting make the true incidence of disease difficult to ... Read more >>

J Blood Med (Journal of blood medicine)
[2019, 10:405-415]

Cited: 4 times

View full text PDF listing >>



Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Yongwei Zheng, Wen Zhu, Dipica Haribhai, Calvin B Williams, Richard H Aster, Renren Wen, Demin Wang,

Heparin-induced thrombocytopenia is a relatively common drug-induced immune disorder that can have life-threatening consequences for affected patients. Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive Abs are central to the pathogenesis of heparin-induced thrombocytopenia. Regulatory T (Treg) cells are a subpopulation of CD4 T cells that play ... Read more >>

J Immunol (Journal of immunology (Baltimore, Md. : 1950))
[2019, 203(7):1786-1792]

Cited: 7 times

View full text PDF listing >>



Beta-lactam-induced severe neutropenia: a descriptive study.

Richard H Aster,

Fundam Clin Pharmacol (Fundamental & clinical pharmacology)
[2019, 33(2):223-224]

Cited: 0 times

View full text PDF listing >>



Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study.

Binod Dhakal, Lisa Baumann Kreuziger, Lisa Rein, Ariel Kleman, Raphael Fraser, Richard H Aster, Parameswaran Hari, Anand Padmanabhan,

<h4>Background</h4>Heparin-induced thrombocytopenia can be a life-threatening and limb-threatening complication of heparin therapy. Incidence and complication rates of this condition have been extrapolated from studies with modest sample sizes, and despite the availability of therapeutic interventions the outcomes of heparin-induced thrombocytopenia are not well understood. We aimed to estimate disease burden, ... Read more >>

Lancet Haematol (The Lancet. Haematology)
[2018, 5(5):e220-e231]

Cited: 15 times

View full text PDF listing >>



Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.

Brian R Curtis, Yen-Michael S Hsu, Nikolai Podoltsev, Jill Lacy, Susanna Curtis, Michael S Samuel, Kristin Zutavern, Robert A DeSimone, Daniel W Bougie, Richard H Aster,

Blood (Blood)
[2018, 131(13):1486-1489]

Cited: 4 times

View full text PDF listing >>



Normal plasma IgG inhibits HIT antibody-mediated platelet activation: implications for therapeutic plasma exchange.

Curtis G Jones, Shannon M Pechauer, Brian R Curtis, Daniel W Bougie, Richard H Aster, Anand Padmanabhan,

Blood (Blood)
[2018, 131(6):703-706]

Cited: 5 times

View full text PDF listing >>



A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies.

Curtis G Jones, Shannon M Pechauer, Brian R Curtis, Daniel W Bougie, Mehraboon S Irani, Binod Dhakal, Brenda Pierce, Richard H Aster, Anand Padmanabhan,

Heparin-induced thrombocytopenia (HIT) is a dangerous complication of heparin therapy. HIT diagnosis is established by recognizing thrombocytopenia and/or thrombosis in an affected patient and from the results of serological tests such as the platelet factor 4 (PF4)/heparin immunoassay (PF4 ELISA) and serotonin release assay (SRA). Recent studies suggest that HIT ... Read more >>

Chest (Chest)
[2017, 152(4):e77-e80]

Cited: 6 times

View full text PDF listing >>



IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

Anand Padmanabhan, Curtis G Jones, Shannon M Pechauer, Brian R Curtis, Daniel W Bougie, Mehraboon S Irani, Barbara J Bryant, Jack B Alperin, Thomas G Deloughery, Kevin P Mulvey, Binod Dhakal, Renren Wen, Demin Wang, Richard H Aster,

<h4>Background</h4>Heparin-induced thrombocytopenia (HIT) complicated by severe thrombocytopenia and thrombosis can pose significant treatment challenges. Use of alternative anticoagulants in this setting may increase bleeding risks, especially in patients who have a protracted disease course. Additional therapies are lacking in this severely affected patient population.<h4>Methods</h4>We describe three patients with HIT who ... Read more >>

Chest (Chest)
[2017, 152(3):478-485]

Cited: 34 times

View full text PDF listing >>



TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.

Dipica Haribhai, Xiaofeng Luo, Juan Chen, Shuang Jia, Linzheng Shi, Jocelyn A Schroeder, Hartmut Weiler, Richard H Aster, Martin J Hessner, Jianda Hu, Calvin B Williams, Qizhen Shi,

Platelets are a rich source of many cytokines and chemokines including transforming growth factor β 1 (TGF-β1). TGF-β1 is required to convert conventional CD4<sup>+</sup> T (Tconv) cells into induced regulatory T (iTreg) cells that express the transcription factor Foxp3. Whether platelet contents will affect Treg cell properties has not been ... Read more >>

Blood Adv (Blood advances)
[2016, 1(2):139-151]

Cited: 7 times

View full text PDF listing >>



Immune destruction of human platelets in the NOD/scid mouse.

Daniel W Bougie, Dhirendra Nayak, Richard H Aster,

Transfusion (Transfusion)
[2016, 56(10):2648-2649]

Cited: 0 times

View full text PDF listing >>



An unexpected development after surgery-post-transfusion purpura!

Gavin Falk, Charles G Winans, Krista Bowens, Daniel W Bougie, Brian R Curtis, Richard H Aster,

Am J Hematol (American journal of hematology)
[2016, 91(8):848-851]

Cited: 5 times

View full text PDF listing >>



A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.

Anand Padmanabhan, Curtis G Jones, Brian R Curtis, Daniel W Bougie, Mia J Sullivan, Namrata Peswani, Janice G McFarland, Daniel Eastwood, Demin Wang, Richard H Aster,

<h4>Background</h4>Almost without exception, patients with heparin-induced thrombocytopenia/thrombosis (HIT) have antibodies that recognize platelet factor 4 (PF4) in a complex with heparin; however, many heparin-treated patients without HIT are also antibody-positive. A platelet activation test, the serotonin release assay (SRA), is useful for identifying a subset of antibodies that are platelet-activating ... Read more >>

Chest (Chest)
[2016, 150(3):506-515]

Cited: 33 times

View full text PDF listing >>



A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation.

Rudy E Fuentes, Sergei Zaitsev, Hyun Sook Ahn, Vincent Hayes, M Anna Kowalska, Michele P Lambert, Yuhuan Wang, Donald L Siegel, Daniel W Bougie, Richard H Aster, Daniel D Myers, Victoria Stepanova, Douglas B Cines, Vladimir R Muzykantov, Mortimer Poncz,

The use of fibrinolytic agents to prevent new thrombus formation is limited by an increased risk of bleeding due to lysis of hemostatic clots that prevent hemorrhage in damaged blood vessels. We sought to develop an agent that provides thromboprophylaxis without carrying a significant risk of causing systemic fibrinolysis or ... Read more >>

J Clin Invest (The Journal of clinical investigation)
[2016, 126(2):483-494]

Cited: 12 times

View full text PDF listing >>



Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa.

Daniel W Bougie, Julie Peterson, Mark Rasmussen, Richard H Aster,

Drug-dependent antibodies (DDAbs) that cause acute thrombocytopenia upon drug exposure are nonreactive in the absence of the drug but bind tightly to a platelet membrane glycoprotein, usually α(IIb)/β3 integrin (GPIIb/IIIa) when the drug is present. How a drug promotes binding of antibody to its target is unknown and is difficult ... Read more >>

Blood (Blood)
[2015, 126(18):2146-2152]

Cited: 11 times

View full text PDF listing >>



Structural basis for quinine-dependent antibody binding to platelet integrin αIIbβ3.

Jianghai Zhu, Jieqing Zhu, Daniel W Bougie, Richard H Aster, Timothy A Springer,

Drug-induced immune thrombocytopenia (DITP) is caused by antibodies that react with specific platelet-membrane glycoproteins when the provoking drug is present. More than 100 drugs have been implicated as triggers for this condition, quinine being one of the most common. The cause of DITP in most cases appears to be a ... Read more >>

Blood (Blood)
[2015, 126(18):2138-2145]

Cited: 14 times

View full text PDF listing >>



A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT.

Anand Padmanabhan, Curtis G Jones, Daniel W Bougie, Brian R Curtis, Janice G McFarland, Demin Wang, Richard H Aster,

Thromb Haemost (Thrombosis and haemostasis)
[2015, 114(6):1322-1323]

Cited: 6 times

View full text PDF listing >>



Drug-Induced Thrombocytopenia following a Transvaginal Oocyte Retrieval for In Vitro Fertilization.

Ioanna A Comstock, Michelle Longmire, Richard H Aster, Amin A Milki,

Drug-induced immune thrombocytopenia has been associated with hundreds of medications and can lead to devastating consequences for the patient. We present a case of a healthy 33-year-old female undergoing in vitro fertilization who developed a severe drug-induced thrombocytopenia, petechiae, and a large hemoperitoneum after receiving Cefazolin antibiotic prophylaxis for a ... Read more >>

Case Rep Obstet Gynecol (Case reports in obstetrics and gynecology)
[2015, 2015:890610]

Cited: 0 times

View full text PDF listing >>



Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.

Jessica A Reese, Daniel W Bougie, Brian R Curtis, Deirdra R Terrell, Sara K Vesely, Richard H Aster, James N George,

Many drugs have been reported to cause thrombotic microangiopathy (TMA), often described as thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS). We recently established criteria to evaluate the evidence for a causal association of a drug with TMA and then we systematically reviewed all published reports of drug-induced TMA (DITMA) ... Read more >>

Am J Hematol (American journal of hematology)
[2015, 90(5):406-410]

Cited: 41 times

View full text PDF listing >>



A new low-frequency alloantigen (Kha(b) ) located on platelet glycoprotein IIIa as a cause of maternal sensitization leading to neonatal alloimmune thrombocytopenia.

Mia J Sullivan, Julie Peterson, Janice G McFarland, Daniel Bougie, Richard H Aster, Brian R Curtis,

Transfusion (Transfusion)
[2015, 55(6 Pt 2):1584-1585]

Cited: 4 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0134 s